BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21114901)

  • 1. Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.
    Sonmez M; Saglam F; Karahan SC; Erkut N; Mentese A; Sonmez B; Ucar F; Topbas M; Ovali E
    Hematology; 2010 Dec; 15(6):391-6. PubMed ID: 21114901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
    Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
    J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.
    Podoltsev NA; Zhu M; Zeidan AM; Wang R; Wang X; Davidoff AJ; Huntington SF; Giri S; Gore SD; Ma X
    Blood Adv; 2018 Oct; 2(20):2681-2690. PubMed ID: 30333100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera: a review.
    Golden C
    Clin J Oncol Nurs; 2003; 7(5):553-6. PubMed ID: 14603552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
    Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.
    Sosothikul D; Seksarn P; Pongsewalak S; Thisyakorn U; Lusher J
    Thromb Haemost; 2007 Apr; 97(4):627-34. PubMed ID: 17393026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
    Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
    Thromb Res; 1998 Apr; 90(2):51-6. PubMed ID: 9684757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
    Silver RT
    Cancer; 2006 Aug; 107(3):451-8. PubMed ID: 16804923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events and intensity of treatment in polycythemia vera.
    Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
    N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
    Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
    Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance evaluation of thrombomodulin, thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, and t-PA: PAI-1 complex.
    Chen Q; Shou W; Wu W; Wang G; Cui W
    J Clin Lab Anal; 2019 Jul; 33(6):e22913. PubMed ID: 31090232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of polycythemia vera.
    Silver RT
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):437-42. PubMed ID: 16810620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.